Charles River Laboratories Intl. (NYSE:CRL) posted its earnings results on Tuesday. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.83 by $0.18, Briefing.com reports. The firm had revenue of $691.10 million during the quarter, compared to analysts’ expectations of $685.46 million. Charles River Laboratories Intl. had a net margin of 9.14% and a return on equity of 21.52%. The company’s revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.49 earnings per share. Charles River Laboratories Intl. updated its FY 2020
Pre-Market guidance to 7.45-7.60 EPS and its FY20 guidance to $7.45-7.60 EPS.
Shares of NYSE CRL traded up $1.23 during midday trading on Friday, reaching $173.53. The company’s stock had a trading volume of 8,173 shares, compared to its average volume of 367,837. The stock has a market capitalization of $7.70 billion, a price-to-earnings ratio of 37.19, a PEG ratio of 1.77 and a beta of 1.18. Charles River Laboratories Intl. has a fifty-two week low of $123.17 and a fifty-two week high of $175.25. The stock has a 50 day simple moving average of $156.97 and a 200-day simple moving average of $140.99. The company has a current ratio of 1.43, a quick ratio of 1.20 and a debt-to-equity ratio of 1.30.
Several research analysts recently commented on CRL shares. Cfra raised their target price on Charles River Laboratories Intl. from $165.00 to $180.00 and gave the stock a “strong-buy” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday. Citigroup lifted their price target on shares of Charles River Laboratories Intl. from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays reiterated a “hold” rating and set a $170.00 target price on shares of Charles River Laboratories Intl. in a research report on Wednesday. Finally, KeyCorp increased their price target on Charles River Laboratories Intl. from $151.00 to $162.00 and gave the company an “overweight” rating in a research note on Monday, December 9th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $168.88.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Featured Story: What does a market perform rating mean?
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.